Publications by authors named "B F Becker"
Background: The lack of clearly defined neuromodulation targets has contributed to the inconsistent results of real-time fMRI-based neurofeedback (rt-fMRI-NF) for the treatment of chronic pain. Functional neurosurgery (funcSurg) approaches have shown more consistent effects in reducing pain in patients with severe chronic pain.
Objective: This study aims to redefine rt-fMRI-NF targets for chronic pain management informed by funcSurg studies.
Background: Sudden cardiac death (SCD) is generally associated with life-threatening ventricular arrhythmias. Supraventricular arrhythmias are an accepted cause of SCD in Wolff-Parkinson-White syndrome and complex congenital heart disease. However, the role of atrial tachyarrhythmias (ATAs) in SCD in patients with structurally normal hearts is unclear.
View Article and Find Full Text PDFArticle Synopsis
- - Deucravacitinib is a new oral medication approved in Japan for treating different types of psoriasis, including plaque, generalized pustular, and erythrodermic psoriasis.
- - The POETYK PSO-4 clinical trial involving 74 Japanese patients showed that the drug was effective and well tolerated, with significant improvements in psoriasis symptoms and quality of life over 52 weeks.
- - Results indicated that about two-thirds of patients achieved a Dermatology Life Quality Index score of 0 or 1 by week 52, although the small number of participants with generalized pustular or erythrodermic psoriasis makes it harder to draw broad conclusions for these types.
Article Synopsis
- This study examined how patient-reported disease burden and health-related quality of life (HRQoL) affect the decision to switch from nonbiologic to biologic therapy in people with plaque psoriasis.
- It included biologic-naive patients aged 18 and older who were using nonbiologic treatments and gathered data on their disease burden and quality of life when they entered the CorEvitas Psoriasis Registry from April 2015 to August 2022.
- Results showed that a higher reported burden was linked to a greater likelihood of switching to biologic treatment, indicating that patient experiences significantly influence treatment decisions alongside clinical assessments.
Background: Drug-resistant hypertension affects approximately 9-18% of the United States hypertensive population. Recognized as hypertension that is resistant to three or more medications, drug-resistant hypertension can lead to fatal sequelae, such as heart failure, aortic dissection, and other vast systemic disease. The disruption of the homeostatic mechanisms that stabilize blood pressure can be treated procedurally when medication fails.
View Article and Find Full Text PDF